Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic, UCB Pharma Expand 1999 Collaboration

NEW YORK, Sept. 6 – Gene Logic has licensed a pair of its technology platforms and a set of gene targets to a business unit of Belgian drug company UCB Pharma, the companies said on Thursday.

Under the deal, which broadens an existing collaboration inked in 1999, UCB Research, of Cambridge, Mass., will gain access to the BioExpress Module of Gene Logic’s GeneExpress suite plus the Genesis Enterprise System, according to a statement.

UCB also has bought an exclusive license to allergy and asthma gene targets and gene-expression data culled form the firms’ original deal, they said.

Financial terms of this recent collaboration were not disclosed. However, the companies said that Gaithersburg, Md.-based Gene Logic “will recognize multi-year revenue” from the two new licensing agreements, as well as “one time revenue” for the gene-targets and -expression data.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.